Articles published by Bristol Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023
October 12, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis
October 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
October 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
October 08, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
MRTX
Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023
September 26, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
September 22, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Announces Dividend
September 20, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
September 14, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Six-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
September 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study
September 09, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research
September 07, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 01, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. FDA Approves Bristol Myers Squibb’s Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
August 28, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Long-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS® (mavacamten) Demonstrate Consistent and Durable Response in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
August 28, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis® or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023
August 25, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
PFE
Bristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments
August 23, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
August 22, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023
August 21, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
August 16, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Inducted into the Billion Dollar Roundtable, Expands Supplier Diversity Efforts
August 10, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Enters Into $4 Billion Aggregate Accelerated Share Repurchase Agreements
August 10, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis
August 08, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
July 27, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
July 21, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Launches Supporting You with UC, with Women’s World Cup Commentator, Former Professional Soccer Player and Ulcerative Colitis Patient, Rosie White
July 12, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Shows Overall Survival and Progression-Free Survival Benefit for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in the Phase 3 CheckMate -901 Trial
July 11, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression ≥1%
June 29, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb Receives European Commission Approval of CAMZYOS® (mavacamten), for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
June 26, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023
June 17, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) Label
June 15, 2023
From
Bristol Myers Squibb
Via
Business Wire
Tickers
BMY
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.